Establishment of a Radiogenomics Consortium

Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY, USA
Radiotherapy and Oncology (Impact Factor: 4.36). 04/2010; 94(1):117–118. DOI: 10.1016/j.radonc.2009.12.007
6 Reads
    • "There is too much discovery and too little validation that involves assessment in multiple independent cohorts and assessment of reproducibility. A consortium approach can increase the size and quality of cohorts studied, for example the Radiogenomics Consortium [13] that is underpinning the discovery of genetic markers of individual radiosensitivity [8]. The development of guidelines for reporting radiotherapy biomarker studies is also needed [14]. "
    Clinical Oncology 07/2015; 27(10). DOI:10.1016/j.clon.2015.06.021 · 3.40 Impact Factor
  • Source
    • "Radiogenomics is a multi-disciplinary scientific research field aiming to link human genomic variability to a cancer patient's likelihood of developing toxicity following radiotherapy [1]. Over 80 publications to date reported results of studies investigating correlations between genetic markers and radiotherapy toxicity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Normal-tissue adverse effects following radiotherapy are common and significantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research. Significance: A single-nucleotide polymorphism–based predictive assay could be used, along with clinical and treatment factors, to estimate the risk that a patient with cancer will develop adverse effects from radiotherapy. Such an assay could be used to personalize therapy and improve quality of life for patients with cancer.
    Cancer Discovery 01/2014; 4(2). DOI:10.1158/2159-8290.CD-13-0197 · 19.45 Impact Factor
  • Source
    • "In response to lack of success in candidate gene studies and the subsequent recognition that this approach is too limited in scope, radiogenomic investigators have now begun a much broader search to identify genes and SNPs associated with radiation response. Several large-scale genome wide association (GWA) studies have been initiated in which radiotherapy patients are being genotyped for large numbers of common SNPs [8, 43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the association between ATM, TP53 and MDM2 polymorphisms in prostate cancer patients and morbidity after radiotherapy. The presence of ATM (rs1801516), TP53 (rs1042522, rs1800371, rs17878362, rs17883323, and rs35117667), and MDM2 (rs2279744) polymorphisms was assessed by direct sequencing of PCR fragments from 48 patients with histologically proven prostate adenocarcinoma and treated with external beam radiation. The side effects were classified according to the Radiation Therapy Oncology Group (RTOG) score. The results showed no association between clinical characteristics and the development of radiation toxicities (P > 0.05). The C>T transition in the position 16273 (intron 3) of TP53 (rs35117667) was significantly associated with the risk of acute skin toxicity (OR: 0.0072, 95% CI 0.0002-0.227, P = 0.003). The intronic TP53 polymorphism at position 16250 (rs17883323) was associated with chronic urinary toxicity (OR: 0.071, 95%CI 0.006-0.784, P = 0.032). No significant associations were found for the remaining polymorphisms (P > 0.05). The results show that clinical characteristics were not determinant on the developing of radiation sensitivity in prostate cancer patients, and intronic TP53 polymorphisms would be associated with increased acute and chronic radiation toxicities. These observations corroborate the importance of investigating the genetic profile to predict adverse side effects in patients undergoing radiotherapy.
    Disease markers 11/2013; 35(6):701-10. DOI:10.1155/2013/762685 · 1.56 Impact Factor
Show more